港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

荃信生物-B

20.460

-0.500-2.39%

成交量：20.22萬

成交額：412.00萬

市值：46.24億

市盈率：-12.15

高：21.040

開：21.040

低：20.080

收：20.960

52周最高：36.500

52周最低：5.950

股本：2.26億

香港流通股本：2.26億

量比：0.95

換手率：0.09%

股息：- -

股息率：- -

每股收益(LYR):-1.683

淨資產收益率：-68.26%

總資產收益率：-10.67%

市淨率：18.56

市盈率(LYR):-12.15

市銷率: 13.11

資料載入中...

總覽公司新聞資訊公告

荃信生物-B(02509)：長效雙抗QX027N獲得兩項臨牀試驗默示許可

港股異動 | 荃信生物-B(02509)漲超10% 擬重續QX001S框架協議年度上限公司自免雙抗價值持續兑現

智通港股回購統計|11月12日

荃信生物-B(02509)11月11日耗資約99.88萬港元回購5.22萬股

透視81家創新藥企三季報：虧損收窄醫保放量BD增長釋放什麼信號？

疾病專題報告(四)：雙抗在自免領域潛力大

荃信生物-B11月10日遭主力拋售62.4萬元

中郵證券-醫藥生物行業週報：自免口服藥物市場存在供需錯配，關注NME帶來的積極轉變-251110

智通港股回購統計|11月10日

BD神話帶不動創新藥了？

荃信生物-B於11月7日斥資607.13萬港元回購30.42萬股

荃信生物-B(02509.HK)11月7日耗資607.1萬港元回購30.4萬股

荃信生物-B(02509)11月6日斥資199.61萬港元回購8.92萬股

藥聞醫訊 | 國家藥監局藥審中心關於發佈《創新藥研發中涉及適老化設計時的一般原則及考慮要點（試行）》的通告（2025年第45號）

巨頭重金入場

药视声Medispace

荃信生物-B盤中異動早盤快速下挫5.66%

港股異動 | 荃信生物-B(02509)盤中漲超11% 旗下QX031N授權羅氏機構稱本次交易具備一定稀缺性

羅氏超10億美元從荃信生物獲得臨牀前呼吸系統雙抗

前三季度對外授權交易超千億美元，國產創新藥迎來新的定價期

港股生物科技板塊集體走弱

每日经济新闻

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02509/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02509","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02509\",,,,,undefined,":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"荃信生物-B","latestPrice":20.46,"timestamp":1765178952283,"preClose":20.96,"halted":0,"volume":202158,"delay":0,"floatShares":225999999,"shares":225999999,"eps":-1.683429371965264,"marketStatus":"交易中","change":-0.5,"latestTime":"12-08 15:31:33","open":21.04,"high":21.04,"low":20.08,"amount":4119962,"amplitude":0.045802,"askPrice":20.54,"askSize":5200,"bidPrice":20.46,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":-0.9506600821713148,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1765181400000},"marketStatusCode":2,"adr":0,"listingDate":1710864000000,"exchange":"SEHK","adjPreClose":20.96,"openAndCloseTimeList":[[1765157400000,1765166400000],[1765170000000,1765180800000]],"volumeRatio":0.952591,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02509\",,,,,undefined,":{"symbol":"02509","floatShares":225999999,"roa":"-10.67%","roe":"-68.26%","lyrEps":-1.683483,"volumeRatio":0.952591,"shares":225999999,"dividePrice":0,"high":21.04,"amplitude":0.045802,"preClose":20.96,"low":20.08,"week52Low":5.95,"pbRate":"18.56","psRate":"13.11","week52High":36.5,"institutionHeld":0,"latestPrice":20.46,"committee":0.315789,"eps":-1.683482971472371,"divideRate":0,"volume":202158,"delay":0,"ttmEps":-0.9506903506890675,"open":21.04,"prevYearClose":7.38,"prevWeekClose":20.96,"prevMonthClose":22.52,"prevQuarterClose":34.88,"fiveDayClose":21.72,"twentyDayClose":19.23,"sixtyDayClose":27.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02509\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"02509","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743125400000,"name":null,"time":"盤後","dateTimestamp":1743091200000,"actualEps":null},{"date":"2024-08-15","symbol":"02509","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1723685400000,"name":null,"time":"","dateTimestamp":1723651200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02509\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02509\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02509\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02509","date":"2025-12-05","current":-22.039495,"percent":0.149289,"low":-38.274716,"twenty":-13.164946,"median":-9.191702,"eighty":-5.178705,"high":-3.10587,"avg":-11.570088,"sd":8.389693,"marketCap":4742036512},"quantilePoints":[{"date":"2024-03-22","current":-9.005941,"twenty":-9.920087,"median":-9.005941,"eighty":-8.797979,"marketCap":4652400020},{"date":"2024-03-28","current":-9.367246,"twenty":-9.484937,"median":-9.005941,"eighty":-8.416995,"marketCap":4821843660},{"date":"2024-04-05","current":-8.872714,"twenty":-9.396669,"median":-8.977885,"eighty":-8.598751,"marketCap":4565907160},{"date":"2024-04-12","current":-9.165919,"twenty":-9.386227,"median":-9.126184,"eighty":-8.830039,"marketCap":4719469060},{"date":"2024-04-19","current":-9.074252,"twenty":-9.304842,"median":-9.125412,"eighty":-8.934406,"marketCap":4668281760},{"date":"2024-04-26","current":-9.882424,"twenty":-9.513374,"median":-9.232059,"eighty":-8.994719,"marketCap":5077780160},{"date":"2024-05-03","current":-10.208268,"twenty":-9.517937,"median":-9.234052,"eighty":-9.046928,"marketCap":5241579520},{"date":"2024-05-10","current":-10.950727,"twenty":-10.058378,"median":-9.328243,"eighty":-9.081967,"marketCap":6018140360},{"date":"2024-05-17","current":-11.513141,"twenty":-10.522167,"median":-9.424295,"eighty":-9.09098,"marketCap":6317937020},{"date":"2024-05-24","current":-11.397533,"twenty":-11.287555,"median":-9.513128,"eighty":-9.098359,"marketCap":6240211960},{"date":"2024-05-31","current":-10.960491,"twenty":-11.380385,"median":-9.702863,"eighty":-9.110289,"marketCap":6007036780},{"date":"2024-06-07","current":-9.736726,"twenty":-11.329803,"median":-9.882424,"eighty":-9.125257,"marketCap":5329718400},{"date":"2024-06-14","current":-9.786262,"twenty":-11.239813,"median":-9.736726,"eighty":-9.134131,"marketCap":5351925560},{"date":"2024-06-21","current":-11.51586,"twenty":-11.394726,"median":-9.834343,"eighty":-9.179147,"marketCap":6284626280},{"date":"2024-06-28","current":-7.449742,"twenty":-11.394726,"median":-9.882424,"eighty":-9.134131,"marketCap":4063910280},{"date":"2024-07-05","current":-8.013266,"twenty":-11.3835,"median":-9.736726,"eighty":-9.096784,"marketCap":4370369088},{"date":"2024-07-12","current":-8.782148,"twenty":-11.375713,"median":-9.612459,"eighty":-8.973485,"marketCap":4796746560},{"date":"2024-07-19","current":-8.033889,"twenty":-11.260937,"median":-9.536435,"eighty":-8.759388,"marketCap":4388134816},{"date":"2024-07-26","current":-8.627957,"twenty":-11.24224,"median":-9.513744,"eighty":-8.627957,"marketCap":4730125080},{"date":"2024-08-02","current":-9.119354,"twenty":-11.155317,"median":-9.51436,"eighty":-8.659337,"marketCap":4996611000},{"date":"2024-08-09","current":-9.602516,"twenty":-11.096166,"median":-9.502501,"eighty":-8.759388,"marketCap":5296407660},{"date":"2024-08-16","current":-9.659156,"twenty":-11.082764,"median":-9.523303,"eighty":-8.782148,"marketCap":5329718400},{"date":"2024-08-23","current":-11.457751,"twenty":-11.24224,"median":-9.560506,"eighty":-8.785621,"marketCap":5274200500},{"date":"2024-08-30","current":-11.261539,"twenty":-11.260937,"median":-9.602516,"eighty":-8.853804,"marketCap":5218682600},{"date":"2024-09-06","current":-12.381731,"twenty":-11.301814,"median":-9.616314,"eighty":-8.872714,"marketCap":5740550860},{"date":"2024-09-13","current":-12.966504,"twenty":-11.41285,"median":-9.666597,"eighty":-8.919616,"marketCap":5995933200},{"date":"2024-09-20","current":-13.175636,"twenty":-11.495182,"median":-9.727036,"eighty":-8.943786,"marketCap":6129176160},{"date":"2024-09-27","current":-11.412309,"twenty":-11.503472,"median":-9.834343,"eighty":-8.968754,"marketCap":5340821980},{"date":"2024-10-04","current":-10.630177,"twenty":-11.500266,"median":-9.955419,"eighty":-8.992959,"marketCap":4952196680},{"date":"2024-10-10","current":-9.640046,"twenty":-11.496891,"median":-9.984689,"eighty":-9.012278,"marketCap":4463639160},{"date":"2024-10-18","current":-7.823087,"twenty":-11.483911,"median":-9.882424,"eighty":-8.891475,"marketCap":3602001352},{"date":"2024-10-25","current":-6.637022,"twenty":-11.464072,"median":-9.731881,"eighty":-8.768492,"marketCap":3055705216},{"date":"2024-11-01","current":-6.266219,"twenty":-11.439791,"median":-9.666597,"eighty":-8.552796,"marketCap":2886930800},{"date":"2024-11-08","current":-6.11978,"twenty":-11.412634,"median":-9.628889,"eighty":-8.354641,"marketCap":2798102160},{"date":"2024-11-15","current":-4.903744,"twenty":-11.406399,"median":-9.610023,"eighty":-8.146037,"marketCap":2225157432},{"date":"2024-11-22","current":-4.446271,"twenty":-11.39192,"median":-9.574881,"eighty":-7.917147,"marketCap":2016410128},{"date":"2024-11-29","current":-5.262129,"twenty":-11.380385,"median":-9.536435,"eighty":-7.700796,"marketCap":2385048984},{"date":"2024-12-06","current":-5.795133,"twenty":-11.346153,"median":-9.513744,"eighty":-7.24659,"marketCap":2620444880},{"date":"2024-12-13","current":-4.23234,"twenty":-11.292835,"median":-9.462151,"eighty":-6.614509,"marketCap":1912036476},{"date":"2024-12-20","current":-3.65763,"twenty":-11.272236,"median":-9.353096,"eighty":-6.423955,"marketCap":1643329840},{"date":"2024-12-27","current":-3.704989,"twenty":-11.261539,"median":-9.289241,"eighty":-6.377951,"marketCap":1663316284},{"date":"2025-01-03","current":-3.459219,"twenty":-11.261057,"median":-9.234052,"eighty":-6.353973,"marketCap":1554501200},{"date":"2025-01-10","current":-3.422771,"twenty":-11.250301,"median":-9.146052,"eighty":-6.232964,"marketCap":1532294040},{"date":"2025-01-17","current":-3.325837,"twenty":-11.24332,"median":-9.119354,"eighty":-5.607796,"marketCap":1490100436},{"date":"2025-01-24","current":-3.940539,"twenty":-11.188065,"median":-9.092192,"eighty":-5.378133,"marketCap":1776572800},{"date":"2025-01-28","current":-4.706176,"twenty":-11.17068,"median":-9.087355,"eighty":-5.266211,"marketCap":2131887360},{"date":"2025-02-07","current":-3.301677,"twenty":-11.154739,"median":-9.066381,"eighty":-4.958001,"marketCap":1487879720},{"date":"2025-02-14","current":-3.418254,"twenty":-11.143754,"median":-8.989713,"eighty":-4.539173,"marketCap":1536735472},{"date":"2025-02-21","current":-3.43891,"twenty":-11.106485,"median":-8.919616,"eighty":-4.354459,"marketCap":1554501200},{"date":"2025-02-28","current":-3.351703,"twenty":-11.093486,"median":-8.819713,"eighty":-4.122814,"marketCap":1510086880},{"date":"2025-03-07","current":-3.387392,"twenty":-11.071174,"median":-8.759388,"eighty":-3.975573,"marketCap":1532294040},{"date":"2025-03-14","current":-5.398225,"twenty":-11.023325,"median":-8.622598,"eighty":-3.975573,"marketCap":2442787600},{"date":"2025-03-21","current":-4.408646,"twenty":-11.005989,"median":-8.475358,"eighty":-3.996365,"marketCap":1994202968},{"date":"2025-03-28","current":-4.427424,"twenty":-10.958538,"median":-8.354936,"eighty":-4.069456,"marketCap":1998644400},{"date":"2025-04-03","current":-5.532239,"twenty":-10.950727,"median":-8.251895,"eighty":-4.071454,"marketCap":1987540820},{"date":"2025-04-11","current":-5.176788,"twenty":-10.949179,"median":-8.134698,"eighty":-4.113712,"marketCap":1843194280},{"date":"2025-04-17","current":-5.605956,"twenty":-10.931954,"median":-8.013266,"eighty":-4.15012,"marketCap":1998644400},{"date":"2025-04-25","current":-6.813611,"twenty":-10.860673,"median":-7.855635,"eighty":-4.203093,"marketCap":2433904736},{"date":"2025-05-02","current":-6.97286,"twenty":-10.741685,"median":-7.823087,"eighty":-4.240312,"marketCap":2496084784},{"date":"2025-05-09","current":-6.850326,"twenty":-10.62989,"median":-7.688151,"eighty":-4.256936,"marketCap":2469436192},{"date":"2025-05-16","current":-6.660384,"twenty":-10.625613,"median":-7.362552,"eighty":-4.28571,"marketCap":2420580440},{"date":"2025-05-23","current":-6.920763,"twenty":-10.596701,"median":-7.188701,"eighty":-4.327055,"marketCap":2522733376},{"date":"2025-05-30","current":-6.975387,"twenty":-10.531077,"median":-7.035719,"eighty":-4.335168,"marketCap":2553823400},{"date":"2025-06-06","current":-8.954176,"twenty":-10.530643,"median":-7.056435,"eighty":-4.354459,"marketCap":3286659680},{"date":"2025-06-13","current":-10.1118,"twenty":-10.525842,"median":-7.245424,"eighty":-4.362058,"marketCap":3713037152},{"date":"2025-06-20","current":-9.295434,"twenty":-10.49786,"median":-7.449742,"eighty":-4.377592,"marketCap":3406578344},{"date":"2025-06-27","current":-9.088195,"twenty":-10.44408,"median":-7.654473,"eighty":-4.399074,"marketCap":3339956864},{"date":"2025-07-04","current":-9.256954,"twenty":-10.441448,"median":-7.771425,"eighty":-4.408646,"marketCap":3402136912},{"date":"2025-07-11","current":-9.278386,"twenty":-10.438605,"median":-7.855635,"eighty":-4.408983,"marketCap":3406578344},{"date":"2025-07-18","current":-10.375245,"twenty":-10.375245,"median":-8.023578,"eighty":-4.415927,"marketCap":3806307224},{"date":"2025-07-25","current":-11.242346,"twenty":-10.444738,"median":-8.163045,"eighty":-4.427424,"marketCap":4139414624},{"date":"2025-08-01","current":-12.956889,"twenty":-10.531115,"median":-8.317696,"eighty":-4.446271,"marketCap":4741228660},{"date":"2025-08-08","current":-12.531071,"twenty":-10.816023,"median":-8.356409,"eighty":-4.497422,"marketCap":4596882120},{"date":"2025-08-15","current":-13.616918,"twenty":-10.950727,"median":-8.486422,"eighty":-4.706176,"marketCap":4987728136},{"date":"2025-08-22","current":-28.922954,"twenty":-11.024815,"median":-8.611071,"eighty":-4.860396,"marketCap":6035906088},{"date":"2025-08-29","current":-26.076607,"twenty":-11.152426,"median":-8.643647,"eighty":-4.89511,"marketCap":5467884128},{"date":"2025-09-05","current":-27.424941,"twenty":-11.24224,"median":-8.759388,"eighty":-4.895913,"marketCap":5744911480},{"date":"2025-09-12","current":-33.976118,"twenty":-11.261539,"median":-8.783884,"eighty":-4.903744,"marketCap":7130048240},{"date":"2025-09-19","current":-32.137812,"twenty":-11.3835,"median":-8.872714,"eighty":-4.920955,"marketCap":6739485088},{"date":"2025-09-26","current":-31.917438,"twenty":-11.446602,"median":-8.942813,"eighty":-4.93749,"marketCap":6675905040},{"date":"2025-10-03","current":-36.693474,"twenty":-11.494681,"median":-8.957754,"eighty":-4.939756,"marketCap":7693185808},{"date":"2025-10-10","current":-31.866218,"twenty":-11.50418,"median":-8.989713,"eighty":-4.971797,"marketCap":6671363608},{"date":"2025-10-17","current":-31.02267,"twenty":-11.536491,"median":-9.052042,"eighty":-5.060821,"marketCap":6489706328},{"date":"2025-10-24","current":-25.824743,"twenty":-11.67702,"median":-9.080681,"eighty":-5.119056,"marketCap":5404304080},{"date":"2025-10-31","current":-23.597698,"twenty":-11.854109,"median":-9.087898,"eighty":-5.129572,"marketCap":4945619448},{"date":"2025-11-07","current":-20.869587,"twenty":-12.197299,"median":-9.096784,"eighty":-5.138538,"marketCap":4371128300},{"date":"2025-11-14","current":-22.685433,"twenty":-12.458841,"median":-9.113568,"eighty":-5.155799,"marketCap":4764920384},{"date":"2025-11-21","current":-21.57415,"twenty":-12.521958,"median":-9.126184,"eighty":-5.17154,"marketCap":4529392000},{"date":"2025-11-28","current":-24.204574,"twenty":-12.94929,"median":-9.16505,"eighty":-5.177501,"marketCap":5100095392},{"date":"2025-12-05","current":-22.466634,"twenty":-13.164946,"median":-9.191702,"eighty":-5.178705,"marketCap":4742036512}],"updateTime":1765154453923},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02509\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2583596530","title":"荃信生物-B(02509)：長效雙抗QX027N獲得兩項臨牀試驗默示許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2583596530","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583596530?lang=zh_tw&edition=fundamental","pubTime":"2025-11-13 22:14","pubTimestamp":1763043269,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，公司自主研发的长效双抗QX027N注射液获得国家药品监督管理局药品审评中心的临床试验默示许可(受理号： CXSL2500757，CXSL2500758)，拟用于治疗哮喘及特应性皮炎。该候选药物的临床许可标志着公司在自免及过敏疾病领域的创新双抗矩阵正式迈入临床阶段。QX027N是公司双特异性抗体研发的重要成果，意味着公司在呼吸和皮肤两大疾病领域的协同布局取得进一步进展。面对全球数亿哮喘与特应性皮炎患者亟待解决的临床需求，公司将持续推进创新疗法的研发与临床转化，为患者提供更高效、更安全及更便利的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2583360475","title":"港股異動 | 荃信生物-B(02509)漲超10% 擬重續QX001S框架協議年度上限 公司自免雙抗價值持續兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2583360475","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583360475?lang=zh_tw&edition=fundamental","pubTime":"2025-11-13 11:07","pubTimestamp":1763003233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荃信生物-B涨超10%，截至发稿，涨10.11%，报20.92港元，成交额1060.24万港元。消息面上，荃信生物日前公告称，董事会已考虑赛乐信商业化后的业务需要，并建议根据QX001S框架协议的条款为2026年至2028年三个财政年度的持续关连交易重续新年度上限。值得一提的是，荃信生物此前宣布与罗氏就其自主研发的长效自免双抗QX031N达成全球独家合作与许可协议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2582314897","title":"智通港股回購統計|11月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=2582314897","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582314897?lang=zh_tw&edition=fundamental","pubTime":"2025-11-12 09:10","pubTimestamp":1762909802,"startTime":"0","endTime":"0","summary":"其中，回购金额最大的为中国飞鹤，回购数量1200.00 万，回购金额5348.00 万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00947","02469","02039","02869","08188","00909","02142","01919","00799","BK1155","LU2097828557.USD","00732","00386","01167","02282","00418","09959","BK1619","02251","02598","01586","00103","LU0348805143.USD","BK1575","01588","06186","06826","LU0828237940.HKD","BK1237","03798","06868","02486","BK1222","BK1170","LU0326950275.SGD","02509","01681","BK1518","01066","00383","BK1160","00777","LU0821914370.USD","BK1519","02171","BK1585","02416","BK1528","02038","02299"],"gpt_icon":0},{"id":"2582643313","title":"荃信生物-B(02509)11月11日耗資約99.88萬港元回購5.22萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582643313","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582643313?lang=zh_tw&edition=fundamental","pubTime":"2025-11-11 21:34","pubTimestamp":1762868064,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)公布，2025年11月11日耗资约99.88万港元回购5.22万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2582357420","title":"透視81家創新藥企三季報：虧損收窄醫保放量BD增長釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2582357420","media":"投资时报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582357420?lang=zh_tw&edition=fundamental","pubTime":"2025-11-11 15:35","pubTimestamp":1762846544,"startTime":"0","endTime":"0","summary":"整体来看，81家A股创新药上市公司归母净利润实现同比增长，增幅达13.84%。数据显示，近年来，中国创新药企业国际授权合作数量不断增加。截至10月21日，2025年中国创新药对外许可交易115起，总金额1012.4亿美元，远超2024年全年519亿美元。11月3日，为期五天的2025年国家医保谈判收官，今年的国家医保谈判，在延续医保目录常规调整机制的基础上，首次引入商保创新药目录新机制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111153610a6f15fdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111153610a6f15fdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","03692","01276","02509","09887","BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2582365617","title":"疾病專題報告(四)：雙抗在自免領域潛力大","url":"https://stock-news.laohu8.com/highlight/detail?id=2582365617","media":"财通证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582365617?lang=zh_tw&edition=fundamental","pubTime":"2025-11-11 00:00","pubTimestamp":1762790400,"startTime":"0","endTime":"0","summary":"由于TCE 的疗效主要来自B 细胞清除能力强弱，因此根据自免疾病特点及B 细胞表面抗原表达周期，我们认为CD3 与CD19/BCMA的组合将是潜力较大的产品，但同时B 细胞清除能力越强，意味着免疫能力越弱，因此对于该类产品需要关注感染及低丙种球蛋白血症的不良反应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111195133a6f1ef51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251111195133a6f1ef51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2582265398","title":"荃信生物-B11月10日遭主力拋售62.4萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582265398","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582265398?lang=zh_tw&edition=fundamental","pubTime":"2025-11-10 16:16","pubTimestamp":1762762565,"startTime":"0","endTime":"0","summary":"11月10日, 荃信生物-B股价跌0.10%，报收19.23元，成交金额1547.2万元，换手率0.36%，振幅8.00%，量比0.99。荃信生物-B今日主力资金净流出62.4万元，上一交易日主力净流出33.2万元。该股近5个交易日下跌17.75%，主力资金累计净流出105.0万元；近20日主力资金累计净流入769.3万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110162344a6eef8f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110162344a6eef8f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2582846287","title":"中郵證券-醫藥生物行業週報：自免口服藥物市場存在供需錯配，關注NME帶來的積極轉變-251110","url":"https://stock-news.laohu8.com/highlight/detail?id=2582846287","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582846287?lang=zh_tw&edition=fundamental","pubTime":"2025-11-10 12:02","pubTimestamp":1762747320,"startTime":"0","endTime":"0","summary":"本周主题本周我们探讨自免领域的口服药物市场价值。自免药物的口服需求庞大，现有疗法存在供需错配。参考NatureReviews，2023年银屑病整体市场为270亿美金，其中口服药物为25亿美金，仅占9%。药物市场主要由IL-23、IL-17和TNF等生物类抑制剂占据。从需求端来看，75%接受注射疗法的病人存在转换为口服的意愿。恒生医疗保健指数下跌2.39%，板块整体跑输恒生指数3.68pct。在恒生12个一级子行业中，医疗保健行业周涨跌幅排名为第12位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110125601a49646b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110125601a49646b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2476274308.USD","LU2488822045.USD","LU0561508036.HKD","LU0634319403.HKD","LU1794554557.SGD","LU0348784397.USD","LU0417516738.SGD","02509","01276","09887","09926","06978","LU1961090484.USD","BK1161","LU0348827113.USD","LU0348767384.USD","LU0348783233.USD","LU0348735423.USD","LU2399975544.HKD","LU2778985437.USD","IE00B543WZ88.USD","03759","LU0348766576.USD","LU0348825331.USD","LU0417516902.SGD","IE00BPRC5H50.USD","BK1574","LU2476274720.SGD","09606","LU0417516571.SGD","LU1720050803.USD","02157","IE00B5MMRT66.SGD","LU0540923850.HKD"],"gpt_icon":0},{"id":"2582812849","title":"智通港股回購統計|11月10日","url":"https://stock-news.laohu8.com/highlight/detail?id=2582812849","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582812849?lang=zh_tw&edition=fundamental","pubTime":"2025-11-10 09:10","pubTimestamp":1762737002,"startTime":"0","endTime":"0","summary":"其中，回购金额最大的为中国飞鹤，回购数量600.00 万，回购金额2608.34 万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00418","02319","02190","02171","02120","01919","09987","09959","02282","06186","00386","01167","08188","09885","LU1023057109.AUD","06868","00103","01066","01586","06826","09966","00366","02869","02018","02057","LU0106959298.USD","SG9999011746.SGD","02598","02299","02469","LU1235295612.USD","00732","02142","01681","02486","02039","00947","02509","LU0385154629.USD","08128","LU2097828557.USD","02416","LU0228659784.USD","00909","01358","00777","02343","02886","00799","01588"],"gpt_icon":0},{"id":"2582816482","title":"BD神話帶不動創新藥了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2582816482","media":"药闻社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582816482?lang=zh_tw&edition=fundamental","pubTime":"2025-11-09 23:12","pubTimestamp":1762701136,"startTime":"0","endTime":"0","summary":"总额高达114亿美元，刷新中国药企BD交易金额记录。MNC倾向靠“堆量”逻辑大批购买中国早期资产，但二级市场流通的钱一共就那么多，投资者在大量雷同交易中渐渐会出现选择犹豫或“祛魅”心态，最终出现“BD带不动创新药”的现象；裂痕已经初见端倪。而目前中国创新药企业交易的BD管线，大部分都属于后面一种情况。2019年，武田以约620亿美元收购Shire，使其背负了巨额债务。和传统BD相比，Co-Co中里程碑付款占总款比例较高，这也","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251109231734a494f4b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251109231734a494f4b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","03692","BK1161","02509","BK1589","02616","BK1583","06978"],"gpt_icon":0},{"id":"2582898108","title":"荃信生物-B於11月7日斥資607.13萬港元回購30.42萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582898108","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582898108?lang=zh_tw&edition=fundamental","pubTime":"2025-11-09 11:17","pubTimestamp":1762658220,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　荃信生物-B（02509）发布公告，于2025年11月7日斥资607.13万港元回购30.42万股。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-11-09/doc-infwunpw8901152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2581188155","title":"荃信生物-B(02509.HK)11月7日耗資607.1萬港元回購30.4萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581188155","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581188155?lang=zh_tw&edition=fundamental","pubTime":"2025-11-07 22:37","pubTimestamp":1762526222,"startTime":"0","endTime":"0","summary":"格隆汇11月7日丨荃信生物-B(02509.HK)公告，11月7日耗资607.1万港元回购30.4万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251107/31777867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2581099087","title":"荃信生物-B(02509)11月6日斥資199.61萬港元回購8.92萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581099087","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581099087?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 22:06","pubTimestamp":1762438003,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，于2025年11月6日斥资199.61万港元回购8.92万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2581605773","title":"藥聞醫訊 | 國家藥監局藥審中心關於發佈《創新藥研發中涉及適老化設計時的一般原則及考慮要點（試行）》的通告（2025年第45號）","url":"https://stock-news.laohu8.com/highlight/detail?id=2581605773","media":"百诚医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581605773?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 17:00","pubTimestamp":1762333206,"startTime":"0","endTime":"0","summary":"国家药监局药审中心关于发布《创新药研发中涉及适老化设计时的一般原则及考虑要点（试行）》的通告；10亿美元！根据《国家药监局综合司关于印发药品技术指导原则发布程序的通知》要求，经国家药品监督管理局审查同意，予以发布，自发布之日起施行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105204305a48aa44a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105204305a48aa44a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02157","06978","BK1574","BK1161","02509"],"gpt_icon":0},{"id":"2581714752","title":"巨頭重金入場","url":"https://stock-news.laohu8.com/highlight/detail?id=2581714752","media":"药视声Medispace","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581714752?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 13:19","pubTimestamp":1762319982,"startTime":"0","endTime":"0","summary":"随着肿瘤和自免领域同质化竞争日益严重，巨头们正在寻找新的增长蓝海。中国COPD患者人数已超过1亿，50岁及以上人群患病率高达23.6%，每年死亡人数超100万人，慢阻肺已成为国人的第三大死因。全球范围内，COPD患者数量约3.842亿，中国市场患者数量占全球总数的四分之一以上。这一差距同时也预示着巨大的市场潜力。重金押注COPD跨国药企一掷千金背后，有着深思熟虑的战略考量。对中国药企而言，COPD领域的创新突破是一个重要的国际化机遇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105132657a489a436&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105132657a489a436&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06955","02162","02509"],"gpt_icon":0},{"id":"2581832708","title":"荃信生物-B盤中異動 早盤快速下挫5.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581832708","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581832708?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 09:35","pubTimestamp":1762306523,"startTime":"0","endTime":"0","summary":"2025年11月05日早盘09时35分，荃信生物-B股票出现波动，股价大幅跳水5.66%。截至发稿，该股报22.000港元/股，成交量9600股，换手率0.00%，振幅4.29%。荃信生物-B股票所在的生物技术行业中，整体跌幅为0.68%。其相关个股中，维升药业-B、药捷安康-B、中生北控生物科技涨幅较大，振幅较大的相关个股有复宏汉霖、永泰生物-B、药捷安康-B，振幅分别为10.67%、8.29%、8.29%。荃信生物-B公司简介：江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110509352394efbdc4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110509352394efbdc4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2580903263","title":"港股異動 | 荃信生物-B(02509)盤中漲超11% 旗下QX031N授權羅氏 機構稱本次交易具備一定稀缺性","url":"https://stock-news.laohu8.com/highlight/detail?id=2580903263","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580903263?lang=zh_tw&edition=fundamental","pubTime":"2025-11-03 14:24","pubTimestamp":1762151061,"startTime":"0","endTime":"0","summary":"消息面上，10月28日，荃信生物宣布与罗氏就其自主研发的长效自免双抗QX031N达成全球独家合作与许可协议。根据协议，罗氏将被授予研究、开发、注册、生产及商业化QX031N的全球独家权益。据悉，QX031N注射液是一款同时靶向TSLP和IL-33的长效双抗。从BD金额和合作方来看，本次交易具备一定稀缺性，QX031N临床价值并不逊色于IBD领域的TL1A双抗，同时亦意味着该靶点组合在全球中具备领先身位和市场潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2579495107","title":"羅氏超10億美元從荃信生物獲得臨牀前呼吸系統雙抗","url":"https://stock-news.laohu8.com/highlight/detail?id=2579495107","media":"Minhua笔记","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579495107?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 20:05","pubTimestamp":1761912322,"startTime":"0","endTime":"0","summary":"罗氏与荃信生物达成全球授权许可协议，以7500万美元首付款加最高9.95亿美元里程金，总价值超10亿美元获得临床前呼吸系统疾病双抗QX031N的全球独家权益。据10月28日提交给香港联交所的文件，罗氏已与荃信生物签署一项全球授权许可协议，获得QX031N的开发和商业化权。该抗体药物靶向两种关键炎症蛋白。与此同时，此次交易也为罗氏在呼吸系统生物药领域提供了又一次机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031212429a6d903b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031212429a6d903b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2579611002","title":"前三季度對外授權交易超千億美元，國產創新藥迎來新的定價期","url":"https://stock-news.laohu8.com/highlight/detail?id=2579611002","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579611002?lang=zh_tw&edition=fundamental","pubTime":"2025-10-30 19:08","pubTimestamp":1761822491,"startTime":"0","endTime":"0","summary":"2025年前三个季度，国产创新药的对外授权交易表现抢眼，二级市场多家创新药企业股价持续走强。交易数量达682笔，首付款为144亿美元，总金额达1910亿美元，均已超过2024年全年水平。若将报告发布后信达生物、荃信生物等交易纳入统计，则2025年前三季度中国创新药对外授权总金额目前已突破1000亿美元。柳丹透露，仅9月份，全球医药授权与并购交易规模已达360亿美元，相当于日均成交额超10亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251030190909a6d6afa1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251030190909a6d6afa1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","LU0502904849.HKD","LU0455707207.USD","02509","LU2488822045.USD","LU1969619763.USD","LU2097828714.EUR","03692","01801","BK1574","01276","LU2097828805.USD","LU2097828474.EUR","LU2328871848.SGD","LU2242644610.SGD","03933","LU2097828557.USD","LU2097828631.EUR","BK1583","BK1161","06978"],"gpt_icon":0},{"id":"2579150721","title":"港股生物科技板塊集體走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=2579150721","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579150721?lang=zh_tw&edition=fundamental","pubTime":"2025-10-30 10:08","pubTimestamp":1761790123,"startTime":"0","endTime":"0","summary":"每经AI快讯，10月30日，港股生物科技板块集体走弱，荃信生物-B、维立志博-B跌超10%，荣昌生物、君实生物、药明生物纷纷下挫。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202510303549808587.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202510303549808587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0307460666.USD","LU0516423174.USD","LU0417516902.SGD","LU3063872942.SGD","LU0326950275.SGD","LU0359202008.SGD","BK4023","LU0456846285.SGD","SG9999002463.SGD","IE00B0JY6N72.USD","LU0043850808.USD","LU0039217434.USD","LU0327786744.USD","02269","LU1688375341.USD","LU0516422366.SGD","LU0320764599.SGD","LU2039709279.SGD","LU0572944931.SGD","LU1720050803.USD","LU0516422440.USD","BK4588","BK1161","BK1521","LU0348825331.USD","LU1794554557.SGD","SG9999002562.SGD","BK4528","LU0516423091.SGD","BK1576","AI","LU0516422952.EUR","LU0823426480.USD","LU0819121731.USD","BK1610","LU1969619763.USD","LU0979878070.USD","02509","BK4543","09995","LU0181495838.USD","LU0456827905.SGD","09887","LU1242518857.USD","BK1141","LU0140636845.USD","LU0708995583.HKD","LU0052750758.USD","BK4551","BK1589"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":118,"code":"91000000","status":"200"}]}}